http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0477274-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
| filingDate | 1990-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72ff28cf9b52b4305b199da542bf81da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a76864f29a27d14f51da4245af57bb9c |
| publicationDate | 1992-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0477274-A1 |
| titleOfInvention | ANTICOAGULANT COMPOSITIONS BASED ON FACTOR Xa. |
| abstract | Anticoagulant composition containing an effective amount of factor Xa comprising the active site of inactivated serine, having a rapid and effective effect in coagulation suppression in vivo. According to a preferred embodiment, factor Xa is first inactivated, a serine esterase forming a complex with factor Va, Ca ++, as well as a phospholipid to catalyze the activation of prothrombin, using an active site inhibitor, such as dansyl-glu-gly-arg-chloromethyl ketone, to form an inactivated factor Xa. According to another embodiment, factor Xa is expressed from a gene sequence, in which the part coding for the active serine region is modified. The inactivated protein retains the ability to bind to an endogenous factor Va in vivo, and has a half-life of approximately ten hours. Administration of inactive factor Xa to the blood of a patient results in the formation of inactive factor Xa-Va complexes in vivo thereby preventing coagulation. |
| priorityDate | 1989-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 61.